Diagnosis and treatment of metastatic colorectal cancer: a review

LH Biller, D Schrag - Jama, 2021 - jamanetwork.com
Colorectal cancer is the third most common cause of cancer … Among people diagnosed
with metastatic colorectal cancer, … The primary treatment for unresectable metastatic CRC is …

The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer

JWG Derksen, SA Kurk, PHM Peeters… - Journal of cachexia …, 2020 - Wiley Online Library
… controlled trial of the Dutch Colorectal Cancer Group that investigated the effect … colorectal
cancer, unresectable metastatic disease, and World Health Organization performance status 0 …

Treatment of metastatic colorectal cancer: ASCO guideline

VK Morris, EB Kennedy, NN Baxter… - Journal of Clinical …, 2023 - ascopubs.org
… , disease-free interval, maximum size of metastases, and WHO performance status, the
estimate of the association of treatment group for OS also showed a significant benefit in favor of …

[HTML][HTML] Survival improvement for patients with metastatic colorectal cancer over twenty years

FA Zeineddine, MA Zeineddine, A Yousef, Y Gu… - NPJ Precision …, 2023 - nature.com
… successive clinical trials in metastatic colorectal cancer (CRC)… the cohort in terms of
performance status or comorbidity, race… higher socioeconomic status, better performance status, …

Trifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer

GW Prager, J Taieb, M Fakih, F Ciardiello… - … England Journal of …, 2023 - Mass Medical Soc
… , many of these patients have a good performance status and may be considered for further
… for third-line treatment of refractory metastatic colorectal cancer on the basis of the results of …

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open …

C Antoniotti, D Rossini, F Pietrantonio… - The Lancet …, 2022 - thelancet.com
… [ECOG] performance status of 0–2 and aged 71–75 years with an ECOG performance status
of 0) … , unresectable, previously untreated metastatic colorectal cancer and adequate organ …

[HTML][HTML] Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis

H Rumpold, D Niedersüß-Beke, C Heiler, D Falch… - BMC cancer, 2020 - Springer
Background Metastatic colorectal cancer (mCRC) remains a lethal disease. Survival, however,
is increasing due to a growing number of treatment options. Yet due to the number of …

[HTML][HTML] Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines

A Grothey, M Fakih, J Tabernero - Annals of Oncology, 2021 - Elsevier
… mCRC are chemotherapy with bevacizumab as well as 5-fluorouracil, leucovorin, oxaliplatin,
and irinotecan (FOLFOXIRI) plus bevacizumab in patients with a good performance status. …

[HTML][HTML] Performance status in cancer: not broken, but time for an upgrade?

JM Scott, G Stene, E Edvardsen… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
… Presurgical CRF stratification values are defined for lung 47 and colorectal cancer, 58
with less than 15 mL O 2 ⋅kg −1 ⋅min −1 associated with an elevated risk of complications, …

… patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer

C Cremolini, C Antoniotti, A Stein, J Bendell… - Journal of Clinical …, 2020 - ascopubs.org
… of patients with ECOG performance status 2 was allowed in … meta-analysis had an ECOG
performance status of 0 or 1, … years of age, an ECOG performance status of 0 was required. The …